Literature DB >> 7592681

Binding of Neu differentiation factor with the extracellular domain of Her2 and Her3.

T Horan1, J Wen, T Arakawa, N Liu, D Brankow, S Hu, B Ratzkin, J S Philo.   

Abstract

The interaction of neu differentiation factor (NDF) with the extracellular domains of Her2 (sHer2) and Her3 (sHer3) have been studied using native gels, light scattering, and sedimentation equilibrium. The full-length NDF beta 2 was shown to bind sHer3 with a dissociation constant of 26 +/- 9 nM, while it showed a 1000-fold weaker binding to sHer2. Taken together, these results demonstrate that NDF is a high affinity ligand for Her3, but not for Her2. No increase in affinity of the NDF beta 2 for sHer3 was observed upon addition of sHer2 to the NDF beta 2-sHer3 mixture. Binding of NDF beta 2 to sHer3 did not induce receptor dimerization or oligomerization, the stoichiometry being one sHer3 per one NDF molecule. This finding suggests that transmembrane and/or intracellular domains of receptor family members or perhaps additional unidentified components may be involved in NDF induced dimerization and autophosphorylation, or alternatively, that dimerization is not the mechanism for Her3 autophosphorylation and signal transduction.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7592681     DOI: 10.1074/jbc.270.41.24604

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  17 in total

Review 1.  Roles of ErbB-3 and ErbB-4 in the physiology and pathology of the mammary gland.

Authors:  K L Carraway; C A Carraway; K L Carraway
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-04       Impact factor: 2.673

2.  A system for quantifying dynamic protein interactions defines a role for Herceptin in modulating ErbB2 interactions.

Authors:  T S Wehrman; W J Raab; C L Casipit; R Doyonnas; J H Pomerantz; H M Blau
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-05       Impact factor: 11.205

3.  Bivalence of EGF-like ligands drives the ErbB signaling network.

Authors:  E Tzahar; R Pinkas-Kramarski; J D Moyer; L N Klapper; I Alroy; G Levkowitz; M Shelly; S Henis; M Eisenstein; B J Ratzkin; M Sela; G C Andrews; Y Yarden
Journal:  EMBO J       Date:  1997-08-15       Impact factor: 11.598

4.  Extracellular domains drive homo- but not hetero-dimerization of erbB receptors.

Authors:  K M Ferguson; P J Darling; M J Mohan; T L Macatee; M A Lemmon
Journal:  EMBO J       Date:  2000-09-01       Impact factor: 11.598

5.  Suppression of heregulin β signaling by the single N-glycan deletion mutant of soluble ErbB3 protein.

Authors:  Motoko Takahashi; Yoshihiro Hasegawa; Yoshitaka Ikeda; Yoshinao Wada; Michiko Tajiri; Shigeru Ariki; Rina Takamiya; Chiaki Nishitani; Motoko Araki; Yoshiki Yamaguchi; Naoyuki Taniguchi; Yoshio Kuroki
Journal:  J Biol Chem       Date:  2013-10-04       Impact factor: 5.157

Review 6.  The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-04-30       Impact factor: 9.867

7.  Signal transduction by epidermal growth factor and heregulin via the kinase-deficient ErbB3 protein.

Authors:  H H Kim; U Vijapurkar; N J Hellyer; D Bravo; J G Koland
Journal:  Biochem J       Date:  1998-08-15       Impact factor: 3.857

Review 8.  Ligand-induced ErbB receptor dimerization.

Authors:  Mark A Lemmon
Journal:  Exp Cell Res       Date:  2008-10-31       Impact factor: 3.905

9.  ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network.

Authors:  R Pinkas-Kramarski; M Shelly; B C Guarino; L M Wang; L Lyass; I Alroy; M Alimandi; A Kuo; J D Moyer; S Lavi; M Eisenstein; B J Ratzkin; R Seger; S S Bacus; J H Pierce; G C Andrews; Y Yarden; M Alamandi
Journal:  Mol Cell Biol       Date:  1998-10       Impact factor: 4.272

10.  ErbB2 resembles an autoinhibited invertebrate epidermal growth factor receptor.

Authors:  Diego Alvarado; Daryl E Klein; Mark A Lemmon
Journal:  Nature       Date:  2009-08-30       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.